A New Era in Oncology

Unlocking the Potential of Immunotherapy

Ability to Potentiate PD-1 Inhibitors

Prolonged Progression Free Survival in PD-1 Resistant Patients

Durable Responses in PD-1 Resistant Patients

We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. Utilizing our proprietary phosphoramidate technology we are developing more effective and safer anti-cancer medicines.

NuCana is led by a highly experienced management team with extensive drug development & commercialization expertise.

Mission Statement

“To significantly improve the survival outcomes for patients and pioneer a new era in oncology”.

Hugh S. Griffith - Founder & CEO

Discover more

Hugh Griffith CEO

Latest News

November 2024

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

November 2024

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

September 2024

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

More news

Contact NuCana

Global Headquarters

3 Lochside Way, Edinburgh, EH12 9DT, UK

info@nucana.com

+ 44 131 357 1111

US Office

275 Grove Street, Newton, MA 02466

info@nucana.com

+1 617 663 5708

* These fields are required.